Department of Clinical Chemistry and Molecular Diagnostics, Poznan University of Medical Sciences, Rokietnicka 3 St., 60-806 Poznan, Poland.
Department of Cancer Immunology, Chair of Medical Biotechnology, Poznan University of Medical Sciences, Garbary 15 St., 61-866 Poznan, Poland.
Int J Mol Sci. 2023 Mar 7;24(6):5099. doi: 10.3390/ijms24065099.
Breast cancer is one of the most frequently observed malignancies worldwide and represents a heterogeneous group of cancers. For this reason, it is crucial to properly diagnose every single case so a specific and efficient therapy can be adjusted. One of the most critical diagnostic parameters evaluated in cancer tissue is the status of the estrogen receptor (ER) and epidermal growth factor receptor (EGFR). Interestingly, the expression of the indicated receptors may be used in a personalized therapy approach. Importantly, the promising role of phytochemicals in the modulation of pathways controlled by ER and EGFR was also demonstrated in several types of cancer. One such biologically active compound is oleanolic acid, but due to poor water solubility and cell membrane permeability that limits its use, alternative derivative compounds were developed. These are HIMOXOL and Br-HIMOLID, which were demonstrated to be capable of inducing apoptosis and autophagy or diminishing the migratory and invasive potential of breast cancer cells in vitro. In our study, we revealed that proliferation, cell cycle, apoptosis, autophagy, and also the migratory potential of HIMOXOL and Br-HIMOLID in breast cancer cells are mediated by ER (MCF7) and EGFR (MDA-MB-231) receptors. These observations make the studied compounds interesting in the context of anticancer strategies.
乳腺癌是全球最常见的恶性肿瘤之一，代表了一组异质性的癌症。因此，正确诊断每一个病例非常重要，以便调整特定且有效的治疗方法。在癌症组织中评估的最关键的诊断参数之一是雌激素受体 (ER) 和表皮生长因子受体 (EGFR) 的状态。有趣的是，指示受体的表达可用于个性化治疗方法。重要的是，植物化学物质在调节 ER 和 EGFR 控制的途径方面的有前途的作用也在几种类型的癌症中得到了证明。一种这样的生物活性化合物是齐墩果酸，但由于其较差的水溶性和细胞膜通透性限制了其用途，因此开发了替代的衍生化合物。这些是 HIMOXOL 和 Br-HIMOLID，它们被证明能够在体外诱导乳腺癌细胞凋亡和自噬，或降低其迁移和侵袭潜力。在我们的研究中，我们揭示了 HIMOXOL 和 Br-HIMOLID 在乳腺癌细胞中的增殖、细胞周期、凋亡、自噬以及迁移潜力是由 ER（MCF7）和 EGFR（MDA-MB-231）受体介导的。这些观察结果使研究的化合物在抗癌策略方面具有吸引力。
